All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $530,000.00 expenses · posted Apr 20, 2026

Official filing document

Lobbying activity 3

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS

Health Issues

GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT

Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.